Biophytis S.A. (BPTSY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biophytis S.A. (BPTSY) with AI Score 45/100 (Weak). Biophytis S. A. is a clinical-stage biotechnology company focused on developing therapeutics for age-related diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Biophytis S.A. (BPTSY) Healthcare & Pipeline Overview
Biophytis S.A. is a clinical-stage biotechnology company developing therapeutics for age-related diseases, including sarcopenia and macular degeneration. Their lead drug candidate, BIO101, addresses neuromuscular diseases and respiratory failure, positioning them in the regenerative medicine market with a focus on resilience pathways.
Investment Thesis
Biophytis S.A. presents a high-risk, high-reward investment opportunity in the biotechnology sector. The investment thesis hinges on the successful clinical development and regulatory approval of BIO101 and BIO201. Key value drivers include positive clinical trial results, strategic partnerships, and potential market exclusivity. The company's focus on age-related diseases aligns with growing demographic trends and unmet medical needs. However, the company's negative P/E ratio of -0.07 reflects its current pre-revenue status. Investors should closely monitor clinical trial outcomes and regulatory milestones as key indicators of future success. The company's low beta of 0.28 suggests lower volatility compared to the broader market, but this may not fully capture the inherent risks of investing in a clinical-stage biotech company.
Based on FMP financials and quantitative analysis
Key Highlights
- Biophytis S.A. is a clinical-stage biotechnology company focused on age-related diseases.
- Lead drug candidate BIO101 targets neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD).
- BIO201 is being developed for retinopathies, such as dry age-related macular degeneration and Stargardt disease.
- Collaboration agreement with AFM-Telethon supports the development of BIO101 for DMD.
- The company's P/E ratio is -0.07, reflecting its pre-revenue status.
Competitors & Peers
Strengths
- Novel approach targeting resilience pathways.
- Lead drug candidate BIO101 in clinical development.
- Collaboration with AFM-Telethon.
- Experienced management team.
Weaknesses
- Clinical-stage company with no current revenue.
- High reliance on successful clinical trial outcomes.
- Limited financial resources.
- OTC market trading with limited liquidity.
Catalysts
- Upcoming: Clinical trial results for BIO101 in sarcopenia patients.
- Upcoming: Clinical trial results for BIO101 in Duchenne Muscular Dystrophy (DMD) patients.
- Upcoming: Regulatory submissions for BIO101 in various indications.
- Ongoing: Advancement of BIO201 into clinical trials for AMD.
- Ongoing: Potential strategic partnerships and licensing agreements.
Risks
- Potential: Clinical trial failures for BIO101 and BIO201.
- Potential: Regulatory delays or rejection of drug candidates.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and need for additional funding.
- Ongoing: OTC market trading with limited liquidity and transparency.
Growth Opportunities
- BIO101 for Sarcopenia: The global sarcopenia market is projected to reach billions of dollars by 2028, driven by the aging population and increasing awareness of muscle loss. BIO101's potential to improve muscle function and reduce the risk of falls presents a significant growth opportunity. Clinical trials are ongoing, and positive results could lead to regulatory approval and commercialization within the next 3-5 years. Biophytis's competitive advantage lies in its focus on resilience pathways and its orally administered small molecule formulation.
- BIO101 for Duchenne Muscular Dystrophy (DMD): DMD is a rare genetic disorder with limited treatment options. BIO101's collaboration with AFM-Telethon provides access to expertise and resources for developing a therapy for DMD. The DMD market is expected to grow as new therapies emerge. Regulatory approval could be expedited through orphan drug designation. The timeline for commercialization depends on the success of clinical trials and regulatory review, potentially within 5-7 years.
- BIO101 for COVID-19 Respiratory Failure: The COVID-19 pandemic has highlighted the need for effective treatments for respiratory failure. BIO101's potential to reduce inflammation and improve lung function could address this unmet need. The market size depends on the ongoing prevalence of COVID-19 and the emergence of new variants. Regulatory approval could be accelerated through emergency use authorization. The timeline for commercialization is uncertain but could be within the next 1-3 years.
- BIO201 for Age-Related Macular Degeneration (AMD): AMD is a leading cause of vision loss in older adults. BIO201's potential to slow the progression of dry AMD represents a significant growth opportunity. The AMD market is expected to grow as the population ages. Clinical trials are planned, and positive results could lead to regulatory approval and commercialization within the next 5-7 years. Biophytis's competitive advantage lies in its focus on resilience pathways and its orally administered small molecule formulation.
- Strategic Partnerships and Licensing Agreements: Biophytis can expand its pipeline and market reach through strategic partnerships and licensing agreements. Collaborating with larger pharmaceutical companies or other biotech firms can provide access to funding, expertise, and distribution networks. Licensing out certain assets can generate revenue and reduce financial risk. The timeline for these opportunities is variable but could occur within the next 1-3 years.
Opportunities
- Growing market for age-related disease therapies.
- Potential for orphan drug designation for DMD.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary drug candidates with patent protection.
- Focus on resilience pathways, a novel approach to treating age-related diseases.
- Collaboration with AFM-Telethon for DMD research.
- Expertise in developing orally administered small molecule drugs.
About BPTSY
Biophytis S.A., founded in 2006 and headquartered in Paris, France, is a clinical-stage biotechnology company dedicated to developing therapeutics that slow degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company's core strategy revolves around targeting and activating key biological resilience pathways, which protect against and counteract the effects of various biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that contribute to age-related diseases. Their lead drug candidate, BIO101, is an orally administered small molecule currently in development for treating neuromuscular diseases such as sarcopenia, Duchenne muscular dystrophy (DMD), and obesity. BIO101 is also being explored as a treatment for severe respiratory failure in patients suffering from COVID-19. In addition to BIO101, Biophytis is developing BIO201, another orally administered small molecule, aimed at treating retinopathies, including dry age-related macular degeneration and Stargardt disease. Biophytis has a collaboration agreement with AFM-Telethon for the development of BIO101 for DMD, highlighting strategic partnerships to advance their pipeline. The company employs 22 individuals.
What They Do
- Develop therapeutics for age-related diseases.
- Target and activate key biological resilience pathways.
- Develop orally administered small molecule drugs.
- Focus on neuromuscular diseases like sarcopenia and DMD.
- Develop treatments for retinopathies like AMD.
- Collaborate with organizations like AFM-Telethon.
Business Model
- Develop and commercialize proprietary drug candidates.
- Out-license drug candidates to larger pharmaceutical companies.
- Generate revenue through strategic partnerships and collaborations.
- Secure funding through venture capital and public offerings.
Industry Context
Biophytis operates within the biotechnology industry, which is characterized by high R&D spending, lengthy regulatory approval processes, and significant market potential for successful therapies. The aging global population is driving increased demand for treatments targeting age-related diseases, creating a favorable market environment for companies like Biophytis. Competition includes established pharmaceutical companies and other biotech firms developing similar therapies. Key trends include personalized medicine, gene therapy, and the use of artificial intelligence in drug discovery. Competitors include BITRF (BioTime Inc), BNGI (Bionomics Ltd), IPIX (Ipix Pharmaceuticals Inc), MCET (MGC Pharmaceuticals Ltd), and PFND (Profound Medical Corp).
Key Customers
- Patients suffering from age-related diseases.
- Healthcare providers who prescribe Biophytis's therapies.
- Pharmaceutical companies that may license or acquire Biophytis's drug candidates.
- Research institutions and organizations interested in collaborating with Biophytis.
Financials
Chart & Info
Biophytis S.A. (BPTSY) stock price: Price data unavailable
Latest News
No recent news available for BPTSY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BPTSY.
Price Targets
Wall Street price target analysis for BPTSY.
MoonshotScore
What does this score mean?
The MoonshotScore rates BPTSY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Stanislas Veillet
CEO
Stanislas Veillet serves as the CEO of Biophytis S.A., bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes roles in venture capital and business development, with a focus on identifying and developing innovative therapies. He has a strong understanding of the regulatory landscape and the challenges of bringing new drugs to market. His leadership is focused on advancing Biophytis's pipeline and securing strategic partnerships.
Track Record: Under Stanislas Veillet's leadership, Biophytis has advanced its lead drug candidate, BIO101, into clinical trials for multiple indications, including sarcopenia and DMD. He has also secured a collaboration agreement with AFM-Telethon, a significant milestone for the company. His strategic decisions have focused on targeting unmet medical needs in age-related diseases and building a strong intellectual property portfolio.
Biophytis S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. BPTSY is a Level 1 ADR, meaning it trades over-the-counter (OTC) and has less stringent reporting requirements than listed companies. It allows US investors to invest in Biophytis S.A. without directly dealing with foreign exchanges.
- Home Market Ticker: Euronext Growth Paris, France
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: BPTS
BPTSY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biophytis S.A. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is considered more speculative and carries higher risks than exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and trading volume.
- Lack of financial transparency and disclosure.
- Higher potential for price manipulation.
- Increased risk of fraud or mismanagement.
- Limited regulatory oversight.
- Review the company's filings on the OTC Markets website.
- Assess the company's financial health and operational performance.
- Research the management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Consult with a financial advisor.
- Consider the risks associated with investing in OTC stocks.
- Established business operations in France.
- Lead drug candidate in clinical development.
- Collaboration agreement with AFM-Telethon.
- Experienced management team.
- Focus on addressing unmet medical needs.
BPTSY Healthcare Stock FAQ
What does Biophytis S.A. do?
Biophytis S.A. is a clinical-stage biotechnology company that focuses on developing therapeutics for age-related diseases. Their primary focus is on activating key biological resilience pathways to counteract the effects of inflammatory, oxidative, metabolic, and viral stresses. Their lead drug candidate, BIO101, is being developed to treat neuromuscular diseases like sarcopenia and Duchenne muscular dystrophy, as well as respiratory failure associated with COVID-19. They are also developing BIO201 for retinopathies such as age-related macular degeneration.
What do analysts say about BPTSY stock?
As of 2026-03-16, there is no available analyst consensus on BPTSY stock. The company's valuation metrics are difficult to assess due to its pre-revenue status. Key growth considerations include the successful completion of clinical trials for BIO101 and BIO201, as well as the ability to secure strategic partnerships and funding. Investors should conduct their own due diligence and consider the risks associated with investing in a clinical-stage biotechnology company.
What are the main risks for BPTSY?
The main risks for Biophytis S.A. include the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. As a clinical-stage company, Biophytis is highly dependent on the successful development and approval of its drug candidates. The company also faces financial risks due to its limited resources and need for additional funding. Trading on the OTC market presents additional risks related to liquidity and transparency.
What are the key factors to evaluate for BPTSY?
Biophytis S.A. (BPTSY) currently holds an AI score of 45/100, indicating low score. Key strength: Novel approach targeting resilience pathways.. Primary risk to monitor: Potential: Clinical trial failures for BIO101 and BIO201.. This is not financial advice.
How frequently does BPTSY data refresh on this page?
BPTSY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BPTSY's recent stock price performance?
Recent price movement in Biophytis S.A. (BPTSY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel approach targeting resilience pathways.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BPTSY overvalued or undervalued right now?
Determining whether Biophytis S.A. (BPTSY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BPTSY?
Before investing in Biophytis S.A. (BPTSY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.